A carregar...
Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. No...
Na minha lista:
Publicado no: | Therap Adv Gastroenterol |
---|---|
Main Authors: | , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
SAGE Publications
2015
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622287/ https://ncbi.nlm.nih.gov/pubmed/26557893 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X15592586 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|